Welcome to our dedicated page for OSR Holdings news (Ticker: OSRH), a resource for investors and traders seeking the latest updates and insights on OSR Holdings stock.
OSR Holdings, Inc. (NASDAQ: OSRH) generates news across multiple areas of healthcare and biotechnology, reflecting its role as a global healthcare holding company focused on immuno-oncology, regenerative biologics, and medical device technologies. The company’s news flow often centers on developments at its key subsidiaries, strategic licensing discussions, clinical data updates, and corporate finance activities.
One major stream of OSR Holdings news relates to Vaximm AG, its Swiss-German immuno-oncology subsidiary. Press releases have detailed Vaximm’s proprietary orally administered T-cell vaccination platform, the clinical progress of lead candidate VXM01 targeting VEGFR-2, and negotiations with BCM Europe AG and affiliated investment vehicles for potential global exclusive licensing arrangements. Updates have covered non-binding and binding term sheets, proposed upfront and milestone payment structures, royalty pass-through mechanisms, and plans to obtain independent fairness opinions, providing insight into how OSR Holdings seeks to unlock value from its immunotherapy assets.
Another important category of news involves Woori IO Co., Ltd., a South Korea-based medical-device company focused on noninvasive glucose monitoring. OSR Holdings has issued releases on the signing and approval of a definitive share exchange agreement under which Woori IO becomes a wholly owned subsidiary of its Korean affiliate, as well as on Woori IO’s collaborations with Samsung Electronics on proof-of-concept studies. News items have also summarized pilot study results for the Glucheck blood glucose measurement system conducted with Korea University Guro Hospital, highlighting accuracy, precision, and ISO 15197:2013 compliance.
Investors following OSRH news will also see announcements about virtual investor events, conference presentations, equity financing arrangements, and Nasdaq listing matters, including notices regarding minimum bid price compliance. This dedicated news page allows readers to track OSR Holdings’ evolving portfolio, licensing initiatives, clinical milestones, and capital markets updates in one place, with new items added as the company furnishes press releases and related SEC communications.
OSR Holdings (NASDAQ:OSRH) CEO Peter Hwang issued a June 3, 2026 letter outlining strategy and Nasdaq compliance efforts. OSRH operates a biomedical portfolio in oncology, regenerative medicine, medical devices, and digital health. Vaximm signed a definitive licensing agreement for the VXM01 immunotherapy platform, described as one of the most significant transactions in company history. Woori IO continues development and strategic engagements, including with Samsung, on a noninvasive glucose monitoring platform. Management is reviewing capital allocation, partnerships, monetizations, and spin-offs while working with Nasdaq to address minimum bid price compliance.
OSR Holdings (NASDAQ:OSRH) signed a definitive Asset Purchase Agreement to acquire the full global VXM01 intellectual property portfolio from VAXIMM for an aggregate $30 million, payable upon the first Phase 2 milestone under the existing BCME license.
The deal centralizes patents, manufacturing know-how, regulatory filings, clinical data, biological materials, and related contracts at the OSRH parent level, complementing OSRH’s prior BCME agreement with up to $815 million in potential milestones, a $15 million put option at $10.00 per share, and rights to 100% downstream royalty economics after BCME recoveries.
OSR Holdings (OSRH) issued a CEO statement on May 12, 2026, confirming it will not pursue a reverse stock split to regain Nasdaq minimum bid compliance. Management plans to restore compliance through operational execution and milestones, not structural actions.
According to OSR Holdings, the company signed definitive agreements with BCM Europe AG for a global exclusive license of oncology asset VXM01, with up to $815 million in potential milestone payments. Subsidiary Woori IO continues its non-invasive glucose monitoring collaboration with Samsung Electronics and NDA-protected discussions with Sinopharm.
OSR Holdings (Nasdaq:OSRH) executed an $815 million exclusive license with BCM Europe AG for VXM01, a Phase-2b/3 ready oral immunotherapy, and completed an $30 million asset purchase transferring VXM01 IP to OSRH. The specialty-financed structure includes a near-term protective put, an expected minimum $15 million cash within six months, and downstream royalties net of BCME’s return hurdle.
Woori IO corporate partnerships and the licensing deal create a potential de-risking event, while risks include operating history, milestone execution, and possible dilution.
OSR Holdings (NASDAQ:OSRH) will present its VXM01 global licensing agreement at the Emerging Growth Conference on May 7, 2026. The virtual presentation is scheduled for 4:10 p.m. ET and will include an overview and a live Q&A.
Tim Smith, Head of Investor Relations, will discuss the recently executed licensing agreement and answer investor questions. Registration is required for live attendance; an archived webcast will be available on EmergingGrowth.com, the Emerging Growth YouTube channel, and the company's Events & Presentations page.
OSR Holdings (NASDAQ:OSRH) entered a definitive global exclusive license with BCM Europe for Phase‑3 ready oral immunotherapy VXM01, creating up to $815 million in milestone payments and acquiring VXM01 IP for $30 million. BCME pledged ~29.7% of OSRH shares as collateral and a $15 million put option at $10.00/share is included. Governing law: Canton of Basel, Switzerland. Independent directors approved the related‑party deal after a fairness opinion.
OSR Holdings (NASDAQ:OSRH) announced a capital-structure transaction with White Lion GBM Innovation Fund to retire approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.
The company issued a $555,555 convertible note (face value increased to $1,055,555 after incorporating extinguished warrants) with a $1.00 fixed conversion price (about a 100% premium to the $0.49 close on April 8, 2026) and a six-month conversion restriction. The transaction is a private placement aimed at reducing dilution risk, supporting NASDAQ minimum-bid compliance, and providing near-term liquidity for corporate purposes.
OSR Holdings (NASDAQ:OSRH) will present strategic updates at the Emerging Growth Conference on April 1, 2026 at 4:25 p.m. ET. The virtual presentation will review recent milestones including the VXM01 oncology asset and Woori IO noninvasive glucose monitoring platform, followed by Q&A.
A live registration link and archived webcast access are provided for investors and analysts who cannot attend live.
OSR Holdings (Nasdaq:OSRH) received a flash report from Emerging Growth Research on March 27, 2026, which reaffirmed a Buy-Emerging rating and a 12-month price target of $10.00.
The report highlights global licensing interest in the non-invasive glucose monitor Woori IO, an NDA with Sinopharm for information exchange in China, an existing licensing term sheet with BCM Europe AG for VXM01, and a potential milestone value of up to $815 million. Management continues investor engagement while noting program early-stage risk, non-binding terms, and potential future dilution.
OSR Holdings (NASDAQ:OSRH) updated the structure of its VXM01 licensing deal with BCM Europe AG to capture economics at the parent level. Up to $815 million in milestone payments will be payable directly to OSR Holdings, plus a $30 million drawable development facility to Vaximm AG.
The company also retains an option to issue up to $15 million of common stock at $10 per share, exercisable six months after the definitive agreement. Digital asset financing provisions are deferred; definitive agreement target remains April 30, 2026, subject to board approval and an independent fairness opinion.